HPV Vaccine Sales Decrease 40% in 2025

Merck today announced its financial results for the first quarter of 2025, which included a significant decrease in sales of its cancer prevention human papillomavirus (HPV) vaccines.

On April 24, 2025, Merck reported that GARDASIL/GARDASIL 9 vaccine sales declined 41% to $1.3 billion in 2025.

This decline is primarily due to lower demand in China, partially offset by higher demand in most international regions, particularly in Japan, as well as higher pricing and demand in the U.S.'

'Excluding China, sales grew 14%, or 16% excluding the impact of foreign exchange.'

Robert M. Davis, chairman and chief executive officer, Merck, commented in a press release, “We are working with focus and urgency to both realize the full potential of our near-term opportunities and to rapidly progress the next wave of innovation that will positively impact the lives of patients and drive future value creation for all of our stakeholders.”

The GARDASIL-9 vaccine remains the leading HPV vaccine in the United States, recommended by the U.S. CDC, and offered at most pharmacies.